Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mast cell score associates with wide-spread mast cell symptoms and comorbidities in patients with hEDS and HSD.

medRxiv : the preprint server for health sciences·2026
Same author

Twenty years of sex and gender science in health research: a policy statement from the Organization for the Study of Sex Differences.

Biology of sex differences·2026
Same author

How biological sex shapes differences in immune responses to infection.

Biology of sex differences·2026
Same author

Importance of integrating biological sex and age analyses in health research.

Biology of sex differences·2026
Same author

Tnni3k Is Cardioprotective in Viral Myocarditis.

Journal of cardiovascular development and disease·2026
Same author

Prevalence of Intracranial and Cervical Artery Abnormalities in Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Presenting to an Academic Headache Clinic.

Neurology international·2026
Same journal

Cell Membrane-Engineered FePDA Nanoparticles Integrate Ferroptosis and Antitumor Immunity.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same journal

Finding the Perfect Match: Investigation of 1,2-Diketone-Based Materials for Use as Cathode Active Material in Rechargeable Magnesium Batteries.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same journal

Stabilization of Cu Species in UiO-66 Metal-Organic Framework for CO<sub>2</sub>-to-Methanol: Insights From Operando X-ray and Electron Microscopy Studies.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same journal

BODIPY Photocage-Based Injectable Hydrogel for Light-Controlled Nanoparticle Release.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same journal

Multifunctional Nanodiamond Conjugate With a Tumor-Specific EGFR-Targeting Peptide and Photoactivated CO Release for Improved Therapeutic Efficacy in Head and Neck Cancers.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same journal

Multifunctional Self-Bonding Biocomposites Enabled by Uniform Dispersion of Carbon Nanotube via In Situ Lignin and Multiple Noncovalent Bonds.

Small (Weinheim an der Bergstrasse, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

936

Reconstituted Extracellular Vesicles from Human Platelets Decrease Viral Myocarditis in Mice.

Danielle J Beetler1,2,3, Katelyn A Bruno2,4, Molly M Watkins1,2,3

  • 1Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, 55902, USA.

Small (Weinheim an Der Bergstrasse, Germany)
|August 24, 2023
PubMed
Summary
This summary is machine-generated.

Platelet-derived extracellular vesicles (EVs) show promise in treating viral myocarditis. These EVs reduce inflammation, improve cardiac function, and decrease fibrosis in mice, offering a potential new therapy for this heart condition.

Keywords:
TLR4cardiomyopathycomplementmicroRNAregenerative medicine

More Related Videos

Purification of Platelets from Mouse Blood
05:41

Purification of Platelets from Mouse Blood

Published on: May 7, 2019

22.3K
Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

15.8K

Related Experiment Videos

Last Updated: Jul 18, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

936
Purification of Platelets from Mouse Blood
05:41

Purification of Platelets from Mouse Blood

Published on: May 7, 2019

22.3K
Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

15.8K

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Regenerative Medicine

Background:

  • Viral myocarditis poses a risk of sudden death and progression to dilated cardiomyopathy (DCM).
  • Current treatments for viral myocarditis lack disease-specific therapies.
  • Extracellular vesicles (EVs) are being investigated for therapeutic potential.

Purpose of the Study:

  • To investigate the efficacy of reconstituted, lyophilized extracellular vesicles (EVs) derived from human platelets in reducing acute and chronic viral myocarditis in a mouse model.
  • To assess the safety and therapeutic effects of platelet-derived EVs (PEV) on cardiac function and inflammatory markers.

Main Methods:

  • Administration of human-platelet-derived EVs (PEV) to male mice during the innate immune response to viral myocarditis.
  • Evaluation of myocarditis severity, immune cell infiltration (F4/80 macrophages, CD4+ and CD8+ T cells, mast cells), cardiac function, and inflammatory mediators (TLR4, complement, IL-1β).
  • Analysis of perivascular fibrosis, cardiac remodeling markers, and microRNA (miRNA) content of PEVs.

Main Results:

  • PEV administration did not cause toxicity or inflammation in naïve mice.
  • PEV treatment significantly reduced myocarditis, decreased inflammatory cell infiltration, and improved cardiac function.
  • PEV treatment lowered levels of myocarditis-promoting mediators like TLR4 and complement, reduced fibrosis and remodeling markers, and inhibited mast cell degranulation.
  • PEV treatment administered later in the disease course (days 7-9) also reduced myocarditis and improved cardiac function.
  • miRNA sequencing revealed PEVs contain miRNAs that target viral replication, TLR4 signaling, and T-cell activation.

Conclusions:

  • Reconstituted, lyophilized EVs from healthy human platelets are safe and effective in reducing viral myocarditis in mice.
  • PEVs significantly improve cardiac function and reduce inflammation, fibrosis, and remodeling associated with myocarditis.
  • PEVs represent a promising cell-free therapeutic strategy for viral myocarditis and its progression to DCM.